In the news

September 2nd, 2024

July 29th, 2024

July 4th, 2024

VICTORIA, BRITISH COLUMBIA (CANADA), June 25, 2024 – ImmunoPrecise Antibodies Ltd. (the “Company” or “IPA”) (NASDAQ: IPA), an AI-driven...

June 13th, 2024

June 13th, 2024

June 7th, 2024

April 2nd, 2024

March 8th, 2024

November 13th, 2023

October 25th, 2023

BioStrand Unveils Groundbreaking Retrieval Augmented Generation (RAG)-Based LLM Platform Integrated with Patented HYFT Technology ...

June 12th, 2023

VICTORIA, British Columbia, June 6, 2023 – ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) (“IPA” or the “Company”) today introduced a...

June 1st, 2023

VICTORIA, British Columbia May 30, 2023 – ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) (“ImmunoPrecise” or “IPA” or the “Company”), an...

April 24th, 2023

Dr. Dirk Van Hyfte, Head of Innovation and Co-Founder at BioStrand, stated, “The integration of HYFT technology into our LLMs marks a...

March 30th, 2023

Agreement Focuses on in silico and de novo Discovery and Development of Antibodies Against Tumor Microenvironment Targets. Program will...

March 27th, 2023

Company Received Official Notice from the European Patent Office (EPO) for the Decision to Grant its Patent Application on April 5th,...

March 15th, 2023

The program will leverage BioStrand’s LENSai® Full Suite of Integrated Intelligence Technology® with Libera Bio’s Multifunctional...

December 8th, 2022

Structural HYFT Technology is used as a navigational layer to parse over the protein predictive platforms AlphaFold-2 and Evolutionary...

November 29th, 2022

VICTORIA, VANCOUVER, BRITISH COLUMBIA (CANADA), and PHILADELPHIA, PA, November 30, 2022 – IPA (IMMUNOPRECISE ANTIBODIES LTD.) ( “IPA”)...

October 12th, 2022